Roche Forced To Wait By FDA For SC Tecentriq Okay
Seven-Minute Injection Recently Approved In UK
The Swiss major’s partner Halozyme has revealed that the US launch for the subcutaneous version of the checkpoint inhibitor Tecentriq will be put back until 2024 following questions from the Food and Drug Administration about manufacturing processes.
